By Rebecca Melvin
New York, April 25 – InRetail Pharma SA priced $400 million of 5 3/8% five-year notes (expected ratings: Ba2//BB+) on Wednesday at 99.676 to yield 5.45%, according to a syndicate source.
Credit Suisse, JPMorgan and Citigroup were joint bookrunners for the Rule 144A and Regulation S deal.
The company is refinancing a bridge loan associated with its acquisition of Quicorp SA in January.
InRetail Pharma is a pharmacy operator based in Lima, Peru.
| Issuer: | InRetail Pharma SA
|
| Issue: | Notes
|
| Amount: | $400 million
|
| Maturity: | May 2, 2023
|
| Bookrunners: | Credit Suisse, JPMorgan and Citigroup
|
| Coupon: | 5 3/8%
|
| Price: | 99.676
|
| Yield: | 5.45%
|
| Calls: | Non-callable for three years
|
| Pricing date: | April 25
|
| Settlement date: | May 2
|
| Ratings: | Moody’s: Ba2
|
| Fitch: BB+
|
| Distribution: | Rule 144A and Regulation S
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
